nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP2D6—Fingolimod—multiple sclerosis	0.0678	0.121	CbGbCtD
Nefazodone—ABCB1—Methylprednisolone—multiple sclerosis	0.0464	0.083	CbGbCtD
Nefazodone—CYP3A4—Fingolimod—multiple sclerosis	0.0431	0.0772	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0359	0.0643	CbGbCtD
Nefazodone—CYP3A7—Dexamethasone—multiple sclerosis	0.0359	0.0643	CbGbCtD
Nefazodone—ABCB1—Mitoxantrone—multiple sclerosis	0.0338	0.0606	CbGbCtD
Nefazodone—ABCB1—Betamethasone—multiple sclerosis	0.0301	0.054	CbGbCtD
Nefazodone—ABCB1—Prednisolone—multiple sclerosis	0.0297	0.0533	CbGbCtD
Nefazodone—ABCB1—Prednisone—multiple sclerosis	0.0281	0.0503	CbGbCtD
Nefazodone—CYP3A4—Methylprednisolone—multiple sclerosis	0.0278	0.0498	CbGbCtD
Nefazodone—CYP3A5—Dexamethasone—multiple sclerosis	0.0269	0.0483	CbGbCtD
Nefazodone—HTR2A—trigeminal nucleus—multiple sclerosis	0.0213	0.206	CbGeAlD
Nefazodone—CYP3A4—Triamcinolone—multiple sclerosis	0.021	0.0377	CbGbCtD
Nefazodone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0203	0.0363	CbGbCtD
Nefazodone—CYP3A4—Betamethasone—multiple sclerosis	0.0181	0.0323	CbGbCtD
Nefazodone—CYP3A4—Prednisolone—multiple sclerosis	0.0178	0.0319	CbGbCtD
Nefazodone—ABCB1—Dexamethasone—multiple sclerosis	0.0175	0.0314	CbGbCtD
Nefazodone—CYP3A4—Prednisone—multiple sclerosis	0.0168	0.0301	CbGbCtD
Nefazodone—CYP2D6—Dexamethasone—multiple sclerosis	0.0165	0.0296	CbGbCtD
Nefazodone—ABCB1—Methotrexate—multiple sclerosis	0.0141	0.0252	CbGbCtD
Nefazodone—CYP3A4—Dexamethasone—multiple sclerosis	0.0105	0.0188	CbGbCtD
Nefazodone—HTR2A—trigeminal nerve—multiple sclerosis	0.0056	0.054	CbGeAlD
Nefazodone—SLC6A3—nerve—multiple sclerosis	0.00422	0.0407	CbGeAlD
Nefazodone—HTR2A—pons—multiple sclerosis	0.00394	0.038	CbGeAlD
Nefazodone—SLC6A2—nerve—multiple sclerosis	0.0034	0.0328	CbGeAlD
Nefazodone—ADRA2A—peripheral nervous system—multiple sclerosis	0.00308	0.0298	CbGeAlD
Nefazodone—HTR2A—pineal body—multiple sclerosis	0.00281	0.0272	CbGeAlD
Nefazodone—HTR2A—peripheral nervous system—multiple sclerosis	0.00262	0.0253	CbGeAlD
Nefazodone—HTR2A—nerve—multiple sclerosis	0.00204	0.0197	CbGeAlD
Nefazodone—SLC6A3—brainstem—multiple sclerosis	0.00181	0.0175	CbGeAlD
Nefazodone—HTR2C—brainstem—multiple sclerosis	0.00175	0.0169	CbGeAlD
Nefazodone—SLC6A4—brainstem—multiple sclerosis	0.00166	0.016	CbGeAlD
Nefazodone—HTR1A—brainstem—multiple sclerosis	0.00147	0.0142	CbGeAlD
Nefazodone—SLC6A2—brainstem—multiple sclerosis	0.00146	0.0141	CbGeAlD
Nefazodone—ADRA1A—brainstem—multiple sclerosis	0.00136	0.0131	CbGeAlD
Nefazodone—ADRA1B—nervous system—multiple sclerosis	0.00127	0.0122	CbGeAlD
Nefazodone—HTR2C—medulla oblongata—multiple sclerosis	0.00122	0.0118	CbGeAlD
Nefazodone—ADRA1B—central nervous system—multiple sclerosis	0.00122	0.0118	CbGeAlD
Nefazodone—SLC6A3—midbrain—multiple sclerosis	0.00115	0.0111	CbGeAlD
Nefazodone—SLC6A3—spinal cord—multiple sclerosis	0.00113	0.0109	CbGeAlD
Nefazodone—HTR2C—midbrain—multiple sclerosis	0.00111	0.0108	CbGeAlD
Nefazodone—HTR2C—spinal cord—multiple sclerosis	0.00109	0.0105	CbGeAlD
Nefazodone—SLC6A4—midbrain—multiple sclerosis	0.00106	0.0102	CbGeAlD
Nefazodone—SLC6A4—spinal cord—multiple sclerosis	0.00103	0.00995	CbGeAlD
Nefazodone—SLC6A2—medulla oblongata—multiple sclerosis	0.00102	0.00983	CbGeAlD
Nefazodone—ADRA1B—brain—multiple sclerosis	0.000967	0.00934	CbGeAlD
Nefazodone—SLC6A3—nervous system—multiple sclerosis	0.000948	0.00915	CbGeAlD
Nefazodone—HTR1A—midbrain—multiple sclerosis	0.000938	0.00906	CbGeAlD
Nefazodone—HTR2C—nervous system—multiple sclerosis	0.000916	0.00885	CbGeAlD
Nefazodone—HTR1A—spinal cord—multiple sclerosis	0.000915	0.00884	CbGeAlD
Nefazodone—SLC6A3—central nervous system—multiple sclerosis	0.000913	0.00881	CbGeAlD
Nefazodone—SLC6A3—cerebellum—multiple sclerosis	0.000892	0.00861	CbGeAlD
Nefazodone—HTR2C—central nervous system—multiple sclerosis	0.000882	0.00852	CbGeAlD
Nefazodone—HTR2A—brainstem—multiple sclerosis	0.000877	0.00847	CbGeAlD
Nefazodone—SLC6A4—nervous system—multiple sclerosis	0.000869	0.00839	CbGeAlD
Nefazodone—HTR2A—retina—multiple sclerosis	0.000846	0.00817	CbGeAlD
Nefazodone—SLC6A4—central nervous system—multiple sclerosis	0.000836	0.00807	CbGeAlD
Nefazodone—CYP2D6—brainstem—multiple sclerosis	0.000799	0.00772	CbGeAlD
Nefazodone—HTR1A—nervous system—multiple sclerosis	0.000771	0.00745	CbGeAlD
Nefazodone—SLC6A2—nervous system—multiple sclerosis	0.000765	0.00738	CbGeAlD
Nefazodone—HTR1A—central nervous system—multiple sclerosis	0.000743	0.00717	CbGeAlD
Nefazodone—SLC6A2—central nervous system—multiple sclerosis	0.000736	0.00711	CbGeAlD
Nefazodone—HTR1A—cerebellum—multiple sclerosis	0.000726	0.00701	CbGeAlD
Nefazodone—SLC6A3—brain—multiple sclerosis	0.000725	0.007	CbGeAlD
Nefazodone—ADRA2A—medulla oblongata—multiple sclerosis	0.00072	0.00695	CbGeAlD
Nefazodone—ADRA1A—nervous system—multiple sclerosis	0.000711	0.00686	CbGeAlD
Nefazodone—HTR2C—brain—multiple sclerosis	0.0007	0.00676	CbGeAlD
Nefazodone—ADRA1A—central nervous system—multiple sclerosis	0.000685	0.00661	CbGeAlD
Nefazodone—ADRA1A—cerebellum—multiple sclerosis	0.000669	0.00646	CbGeAlD
Nefazodone—SLC6A4—brain—multiple sclerosis	0.000664	0.00641	CbGeAlD
Nefazodone—ADRA2A—midbrain—multiple sclerosis	0.000658	0.00635	CbGeAlD
Nefazodone—ADRA2A—spinal cord—multiple sclerosis	0.000642	0.00619	CbGeAlD
Nefazodone—HTR2A—medulla oblongata—multiple sclerosis	0.000612	0.00591	CbGeAlD
Nefazodone—HTR1A—brain—multiple sclerosis	0.00059	0.00569	CbGeAlD
Nefazodone—SLC6A2—brain—multiple sclerosis	0.000585	0.00564	CbGeAlD
Nefazodone—HTR2A—midbrain—multiple sclerosis	0.000559	0.0054	CbGeAlD
Nefazodone—ABCB1—retina—multiple sclerosis	0.000555	0.00535	CbGeAlD
Nefazodone—HTR2A—spinal cord—multiple sclerosis	0.000546	0.00527	CbGeAlD
Nefazodone—ADRA1A—brain—multiple sclerosis	0.000543	0.00525	CbGeAlD
Nefazodone—ADRA2A—nervous system—multiple sclerosis	0.000541	0.00522	CbGeAlD
Nefazodone—ADRA2A—central nervous system—multiple sclerosis	0.00052	0.00502	CbGeAlD
Nefazodone—ADRA2A—cerebellum—multiple sclerosis	0.000509	0.00491	CbGeAlD
Nefazodone—HTR2A—nervous system—multiple sclerosis	0.00046	0.00444	CbGeAlD
Nefazodone—HTR2A—central nervous system—multiple sclerosis	0.000443	0.00427	CbGeAlD
Nefazodone—HTR2A—cerebellum—multiple sclerosis	0.000433	0.00418	CbGeAlD
Nefazodone—CYP3A4—nervous system—multiple sclerosis	0.000426	0.00411	CbGeAlD
Nefazodone—CYP2D6—nervous system—multiple sclerosis	0.000419	0.00404	CbGeAlD
Nefazodone—ADRA2A—brain—multiple sclerosis	0.000413	0.00399	CbGeAlD
Nefazodone—CYP3A4—central nervous system—multiple sclerosis	0.00041	0.00396	CbGeAlD
Nefazodone—CYP2D6—central nervous system—multiple sclerosis	0.000403	0.00389	CbGeAlD
Nefazodone—ABCB1—medulla oblongata—multiple sclerosis	0.000401	0.00387	CbGeAlD
Nefazodone—CYP2D6—cerebellum—multiple sclerosis	0.000394	0.0038	CbGeAlD
Nefazodone—ABCB1—midbrain—multiple sclerosis	0.000366	0.00354	CbGeAlD
Nefazodone—ABCB1—spinal cord—multiple sclerosis	0.000358	0.00345	CbGeAlD
Nefazodone—HTR2A—brain—multiple sclerosis	0.000351	0.00339	CbGeAlD
Nefazodone—CYP2D6—brain—multiple sclerosis	0.00032	0.00309	CbGeAlD
Nefazodone—ABCB1—nervous system—multiple sclerosis	0.000301	0.00291	CbGeAlD
Nefazodone—ABCB1—central nervous system—multiple sclerosis	0.00029	0.0028	CbGeAlD
Nefazodone—ABCB1—cerebellum—multiple sclerosis	0.000283	0.00274	CbGeAlD
Nefazodone—ABCB1—brain—multiple sclerosis	0.00023	0.00222	CbGeAlD
Nefazodone—Dry mouth—Triamcinolone—multiple sclerosis	0.000229	0.000892	CcSEcCtD
Nefazodone—Angioedema—Dexamethasone—multiple sclerosis	0.000228	0.000888	CcSEcCtD
Nefazodone—Angioedema—Betamethasone—multiple sclerosis	0.000228	0.000888	CcSEcCtD
Nefazodone—Stomatitis—Methotrexate—multiple sclerosis	0.000227	0.000883	CcSEcCtD
Nefazodone—Conjunctivitis—Methotrexate—multiple sclerosis	0.000226	0.00088	CcSEcCtD
Nefazodone—Confusional state—Methylprednisolone—multiple sclerosis	0.000226	0.00088	CcSEcCtD
Nefazodone—Malaise—Betamethasone—multiple sclerosis	0.000225	0.000877	CcSEcCtD
Nefazodone—Malaise—Dexamethasone—multiple sclerosis	0.000225	0.000877	CcSEcCtD
Nefazodone—Oedema—Triamcinolone—multiple sclerosis	0.000225	0.000875	CcSEcCtD
Nefazodone—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000225	0.000875	CcSEcCtD
Nefazodone—Vertigo—Dexamethasone—multiple sclerosis	0.000224	0.000874	CcSEcCtD
Nefazodone—Vertigo—Betamethasone—multiple sclerosis	0.000224	0.000874	CcSEcCtD
Nefazodone—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000224	0.000873	CcSEcCtD
Nefazodone—Syncope—Betamethasone—multiple sclerosis	0.000224	0.000872	CcSEcCtD
Nefazodone—Syncope—Dexamethasone—multiple sclerosis	0.000224	0.000872	CcSEcCtD
Nefazodone—Infection—Triamcinolone—multiple sclerosis	0.000223	0.000869	CcSEcCtD
Nefazodone—Sweating—Methotrexate—multiple sclerosis	0.000223	0.000868	CcSEcCtD
Nefazodone—Infection—Methylprednisolone—multiple sclerosis	0.000223	0.000867	CcSEcCtD
Nefazodone—Haematuria—Methotrexate—multiple sclerosis	0.000222	0.000863	CcSEcCtD
Nefazodone—Shock—Triamcinolone—multiple sclerosis	0.000221	0.00086	CcSEcCtD
Nefazodone—Insomnia—Prednisolone—multiple sclerosis	0.000221	0.00086	CcSEcCtD
Nefazodone—Alopecia—Prednisone—multiple sclerosis	0.000221	0.000859	CcSEcCtD
Nefazodone—Shock—Methylprednisolone—multiple sclerosis	0.000221	0.000858	CcSEcCtD
Nefazodone—Loss of consciousness—Dexamethasone—multiple sclerosis	0.00022	0.000855	CcSEcCtD
Nefazodone—Loss of consciousness—Betamethasone—multiple sclerosis	0.00022	0.000855	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—multiple sclerosis	0.000219	0.000854	CcSEcCtD
Nefazodone—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000219	0.000854	CcSEcCtD
Nefazodone—Paraesthesia—Prednisolone—multiple sclerosis	0.000219	0.000854	CcSEcCtD
Nefazodone—Tachycardia—Triamcinolone—multiple sclerosis	0.000219	0.000853	CcSEcCtD
Nefazodone—Nausea—Azathioprine—multiple sclerosis	0.000219	0.000852	CcSEcCtD
Nefazodone—Tachycardia—Methylprednisolone—multiple sclerosis	0.000219	0.000852	CcSEcCtD
Nefazodone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000217	0.000845	CcSEcCtD
Nefazodone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000217	0.000844	CcSEcCtD
Nefazodone—Convulsion—Dexamethasone—multiple sclerosis	0.000216	0.000842	CcSEcCtD
Nefazodone—Convulsion—Betamethasone—multiple sclerosis	0.000216	0.000842	CcSEcCtD
Nefazodone—Hypertension—Dexamethasone—multiple sclerosis	0.000216	0.000839	CcSEcCtD
Nefazodone—Hypertension—Betamethasone—multiple sclerosis	0.000216	0.000839	CcSEcCtD
Nefazodone—Asthenia—Mitoxantrone—multiple sclerosis	0.000214	0.000832	CcSEcCtD
Nefazodone—Myalgia—Dexamethasone—multiple sclerosis	0.000213	0.000828	CcSEcCtD
Nefazodone—Myalgia—Betamethasone—multiple sclerosis	0.000213	0.000828	CcSEcCtD
Nefazodone—Anxiety—Betamethasone—multiple sclerosis	0.000212	0.000825	CcSEcCtD
Nefazodone—Anxiety—Dexamethasone—multiple sclerosis	0.000212	0.000825	CcSEcCtD
Nefazodone—Discomfort—Betamethasone—multiple sclerosis	0.00021	0.000818	CcSEcCtD
Nefazodone—Discomfort—Dexamethasone—multiple sclerosis	0.00021	0.000818	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—multiple sclerosis	0.00021	0.000817	CcSEcCtD
Nefazodone—Hypotension—Methylprednisolone—multiple sclerosis	0.000209	0.000815	CcSEcCtD
Nefazodone—Pain—Prednisolone—multiple sclerosis	0.000209	0.000813	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—multiple sclerosis	0.000209	0.000813	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—multiple sclerosis	0.000209	0.000813	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—multiple sclerosis	0.000207	0.000807	CcSEcCtD
Nefazodone—Vision blurred—Prednisone—multiple sclerosis	0.000205	0.000798	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000205	0.000797	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000204	0.000795	CcSEcCtD
Nefazodone—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000204	0.000793	CcSEcCtD
Nefazodone—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000204	0.000793	CcSEcCtD
Nefazodone—Oedema—Dexamethasone—multiple sclerosis	0.000204	0.000793	CcSEcCtD
Nefazodone—Oedema—Betamethasone—multiple sclerosis	0.000204	0.000793	CcSEcCtD
Nefazodone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000204	0.000793	CcSEcCtD
Nefazodone—Insomnia—Triamcinolone—multiple sclerosis	0.000203	0.000791	CcSEcCtD
Nefazodone—Insomnia—Methylprednisolone—multiple sclerosis	0.000203	0.000789	CcSEcCtD
Nefazodone—Infection—Betamethasone—multiple sclerosis	0.000203	0.000788	CcSEcCtD
Nefazodone—Infection—Dexamethasone—multiple sclerosis	0.000203	0.000788	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisone—multiple sclerosis	0.000202	0.000786	CcSEcCtD
Nefazodone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000202	0.000785	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000201	0.000784	CcSEcCtD
Nefazodone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000201	0.000784	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—multiple sclerosis	0.000201	0.000783	CcSEcCtD
Nefazodone—Anaemia—Prednisone—multiple sclerosis	0.000201	0.000783	CcSEcCtD
Nefazodone—Shock—Betamethasone—multiple sclerosis	0.000201	0.000781	CcSEcCtD
Nefazodone—Shock—Dexamethasone—multiple sclerosis	0.000201	0.000781	CcSEcCtD
Nefazodone—Dyspnoea—Triamcinolone—multiple sclerosis	0.0002	0.00078	CcSEcCtD
Nefazodone—Agitation—Prednisone—multiple sclerosis	0.0002	0.000778	CcSEcCtD
Nefazodone—Thrombocytopenia—Betamethasone—multiple sclerosis	0.0002	0.000777	CcSEcCtD
Nefazodone—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.0002	0.000777	CcSEcCtD
Nefazodone—Tachycardia—Betamethasone—multiple sclerosis	0.000199	0.000774	CcSEcCtD
Nefazodone—Tachycardia—Dexamethasone—multiple sclerosis	0.000199	0.000774	CcSEcCtD
Nefazodone—Angioedema—Prednisone—multiple sclerosis	0.000199	0.000774	CcSEcCtD
Nefazodone—Dyspepsia—Triamcinolone—multiple sclerosis	0.000198	0.00077	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—multiple sclerosis	0.000197	0.000769	CcSEcCtD
Nefazodone—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000197	0.000768	CcSEcCtD
Nefazodone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000197	0.000767	CcSEcCtD
Nefazodone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000197	0.000767	CcSEcCtD
Nefazodone—Malaise—Prednisone—multiple sclerosis	0.000196	0.000764	CcSEcCtD
Nefazodone—Vertigo—Prednisone—multiple sclerosis	0.000195	0.000761	CcSEcCtD
Nefazodone—Syncope—Prednisone—multiple sclerosis	0.000195	0.000759	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—multiple sclerosis	0.000195	0.000758	CcSEcCtD
Nefazodone—Anorexia—Dexamethasone—multiple sclerosis	0.000194	0.000756	CcSEcCtD
Nefazodone—Anorexia—Betamethasone—multiple sclerosis	0.000194	0.000756	CcSEcCtD
Nefazodone—Urticaria—Prednisolone—multiple sclerosis	0.000194	0.000755	CcSEcCtD
Nefazodone—Pain—Triamcinolone—multiple sclerosis	0.000192	0.000748	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—multiple sclerosis	0.000191	0.000744	CcSEcCtD
Nefazodone—Hypotension—Dexamethasone—multiple sclerosis	0.00019	0.000741	CcSEcCtD
Nefazodone—Hypotension—Betamethasone—multiple sclerosis	0.00019	0.000741	CcSEcCtD
Nefazodone—Vomiting—Mitoxantrone—multiple sclerosis	0.000189	0.000737	CcSEcCtD
Nefazodone—Convulsion—Prednisone—multiple sclerosis	0.000188	0.000734	CcSEcCtD
Nefazodone—Hypertension—Prednisone—multiple sclerosis	0.000188	0.000731	CcSEcCtD
Nefazodone—Rash—Mitoxantrone—multiple sclerosis	0.000188	0.000731	CcSEcCtD
Nefazodone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000188	0.00073	CcSEcCtD
Nefazodone—Chills—Methotrexate—multiple sclerosis	0.000187	0.000729	CcSEcCtD
Nefazodone—Headache—Mitoxantrone—multiple sclerosis	0.000187	0.000726	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000186	0.000723	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000186	0.000723	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—multiple sclerosis	0.000185	0.000721	CcSEcCtD
Nefazodone—Myalgia—Prednisone—multiple sclerosis	0.000185	0.000721	CcSEcCtD
Nefazodone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000185	0.000721	CcSEcCtD
Nefazodone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000185	0.000719	CcSEcCtD
Nefazodone—Anxiety—Prednisone—multiple sclerosis	0.000185	0.000718	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—multiple sclerosis	0.000185	0.000718	CcSEcCtD
Nefazodone—Insomnia—Dexamethasone—multiple sclerosis	0.000184	0.000718	CcSEcCtD
Nefazodone—Insomnia—Betamethasone—multiple sclerosis	0.000184	0.000718	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000183	0.000714	CcSEcCtD
Nefazodone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000183	0.000713	CcSEcCtD
Nefazodone—Paraesthesia—Betamethasone—multiple sclerosis	0.000183	0.000713	CcSEcCtD
Nefazodone—Discomfort—Prednisone—multiple sclerosis	0.000183	0.000712	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisolone—multiple sclerosis	0.00018	0.000701	CcSEcCtD
Nefazodone—Dyspepsia—Dexamethasone—multiple sclerosis	0.000179	0.000698	CcSEcCtD
Nefazodone—Dyspepsia—Betamethasone—multiple sclerosis	0.000179	0.000698	CcSEcCtD
Nefazodone—Urticaria—Triamcinolone—multiple sclerosis	0.000178	0.000695	CcSEcCtD
Nefazodone—Urticaria—Methylprednisolone—multiple sclerosis	0.000178	0.000693	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—multiple sclerosis	0.000178	0.000693	CcSEcCtD
Nefazodone—Body temperature increased—Triamcinolone—multiple sclerosis	0.000178	0.000691	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—multiple sclerosis	0.000178	0.000691	CcSEcCtD
Nefazodone—Oedema—Prednisone—multiple sclerosis	0.000178	0.000691	CcSEcCtD
Nefazodone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000177	0.00069	CcSEcCtD
Nefazodone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000177	0.00069	CcSEcCtD
Nefazodone—Decreased appetite—Betamethasone—multiple sclerosis	0.000177	0.00069	CcSEcCtD
Nefazodone—Nausea—Mitoxantrone—multiple sclerosis	0.000177	0.000688	CcSEcCtD
Nefazodone—Infection—Prednisone—multiple sclerosis	0.000176	0.000687	CcSEcCtD
Nefazodone—Back pain—Methotrexate—multiple sclerosis	0.000176	0.000684	CcSEcCtD
Nefazodone—Shock—Prednisone—multiple sclerosis	0.000175	0.00068	CcSEcCtD
Nefazodone—Pain—Dexamethasone—multiple sclerosis	0.000174	0.000679	CcSEcCtD
Nefazodone—Pain—Betamethasone—multiple sclerosis	0.000174	0.000679	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—multiple sclerosis	0.000173	0.000674	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000172	0.000668	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—multiple sclerosis	0.000171	0.000667	CcSEcCtD
Nefazodone—Anorexia—Prednisone—multiple sclerosis	0.000169	0.000659	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000169	0.000657	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—multiple sclerosis	0.000168	0.000654	CcSEcCtD
Nefazodone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000168	0.000654	CcSEcCtD
Nefazodone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000168	0.000654	CcSEcCtD
Nefazodone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000167	0.000649	CcSEcCtD
Nefazodone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000167	0.000649	CcSEcCtD
Nefazodone—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000166	0.000644	CcSEcCtD
Nefazodone—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000165	0.000643	CcSEcCtD
Nefazodone—Malaise—Methotrexate—multiple sclerosis	0.000164	0.000638	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—multiple sclerosis	0.000163	0.000636	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—multiple sclerosis	0.000163	0.000633	CcSEcCtD
Nefazodone—Urticaria—Betamethasone—multiple sclerosis	0.000162	0.00063	CcSEcCtD
Nefazodone—Urticaria—Dexamethasone—multiple sclerosis	0.000162	0.00063	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000162	0.00063	CcSEcCtD
Nefazodone—Dizziness—Prednisolone—multiple sclerosis	0.000162	0.000629	CcSEcCtD
Nefazodone—Asthenia—Triamcinolone—multiple sclerosis	0.000161	0.000627	CcSEcCtD
Nefazodone—Abdominal pain—Betamethasone—multiple sclerosis	0.000161	0.000627	CcSEcCtD
Nefazodone—Abdominal pain—Dexamethasone—multiple sclerosis	0.000161	0.000627	CcSEcCtD
Nefazodone—Body temperature increased—Dexamethasone—multiple sclerosis	0.000161	0.000627	CcSEcCtD
Nefazodone—Body temperature increased—Betamethasone—multiple sclerosis	0.000161	0.000627	CcSEcCtD
Nefazodone—Asthenia—Methylprednisolone—multiple sclerosis	0.000161	0.000626	CcSEcCtD
Nefazodone—Insomnia—Prednisone—multiple sclerosis	0.000161	0.000625	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—multiple sclerosis	0.000159	0.000621	CcSEcCtD
Nefazodone—Pruritus—Triamcinolone—multiple sclerosis	0.000159	0.000619	CcSEcCtD
Nefazodone—Cough—Methotrexate—multiple sclerosis	0.000159	0.000617	CcSEcCtD
Nefazodone—Pruritus—Methylprednisolone—multiple sclerosis	0.000159	0.000617	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—multiple sclerosis	0.000158	0.000613	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—multiple sclerosis	0.000156	0.000608	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—multiple sclerosis	0.000155	0.000602	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—multiple sclerosis	0.000155	0.000602	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—multiple sclerosis	0.000155	0.000602	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—multiple sclerosis	0.000154	0.000601	CcSEcCtD
Nefazodone—Rash—Prednisolone—multiple sclerosis	0.000154	0.0006	CcSEcCtD
Nefazodone—Dermatitis—Prednisolone—multiple sclerosis	0.000154	0.000599	CcSEcCtD
Nefazodone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000153	0.000597	CcSEcCtD
Nefazodone—Headache—Prednisolone—multiple sclerosis	0.000153	0.000596	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—multiple sclerosis	0.000153	0.000595	CcSEcCtD
Nefazodone—Constipation—Prednisone—multiple sclerosis	0.000152	0.000591	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—multiple sclerosis	0.00015	0.000582	CcSEcCtD
Nefazodone—Dizziness—Triamcinolone—multiple sclerosis	0.000149	0.000578	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000148	0.000578	CcSEcCtD
Nefazodone—Dizziness—Methylprednisolone—multiple sclerosis	0.000148	0.000577	CcSEcCtD
Nefazodone—Infection—Methotrexate—multiple sclerosis	0.000147	0.000574	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Nefazodone—Asthenia—Betamethasone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Nefazodone—Asthenia—Dexamethasone—multiple sclerosis	0.000146	0.000569	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000145	0.000565	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000145	0.000565	CcSEcCtD
Nefazodone—Nausea—Prednisolone—multiple sclerosis	0.000145	0.000565	CcSEcCtD
Nefazodone—Pruritus—Betamethasone—multiple sclerosis	0.000144	0.000561	CcSEcCtD
Nefazodone—Pruritus—Dexamethasone—multiple sclerosis	0.000144	0.000561	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000143	0.000558	CcSEcCtD
Nefazodone—Vomiting—Triamcinolone—multiple sclerosis	0.000143	0.000556	CcSEcCtD
Nefazodone—Vomiting—Methylprednisolone—multiple sclerosis	0.000143	0.000555	CcSEcCtD
Nefazodone—Rash—Triamcinolone—multiple sclerosis	0.000142	0.000551	CcSEcCtD
Nefazodone—Dermatitis—Triamcinolone—multiple sclerosis	0.000142	0.000551	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—multiple sclerosis	0.000141	0.00055	CcSEcCtD
Nefazodone—Rash—Methylprednisolone—multiple sclerosis	0.000141	0.00055	CcSEcCtD
Nefazodone—Dermatitis—Methylprednisolone—multiple sclerosis	0.000141	0.00055	CcSEcCtD
Nefazodone—Urticaria—Prednisone—multiple sclerosis	0.000141	0.000549	CcSEcCtD
Nefazodone—Headache—Triamcinolone—multiple sclerosis	0.000141	0.000548	CcSEcCtD
Nefazodone—Headache—Methylprednisolone—multiple sclerosis	0.00014	0.000547	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—multiple sclerosis	0.00014	0.000546	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—multiple sclerosis	0.00014	0.000546	CcSEcCtD
Nefazodone—Diarrhoea—Dexamethasone—multiple sclerosis	0.000139	0.000543	CcSEcCtD
Nefazodone—Diarrhoea—Betamethasone—multiple sclerosis	0.000139	0.000543	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—multiple sclerosis	0.000139	0.00054	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000135	0.000526	CcSEcCtD
Nefazodone—Dizziness—Dexamethasone—multiple sclerosis	0.000135	0.000525	CcSEcCtD
Nefazodone—Dizziness—Betamethasone—multiple sclerosis	0.000135	0.000525	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—multiple sclerosis	0.000134	0.000522	CcSEcCtD
Nefazodone—Nausea—Triamcinolone—multiple sclerosis	0.000133	0.000519	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—multiple sclerosis	0.000133	0.000519	CcSEcCtD
Nefazodone—Nausea—Methylprednisolone—multiple sclerosis	0.000133	0.000518	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—multiple sclerosis	0.000132	0.000515	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—multiple sclerosis	0.000132	0.000513	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—multiple sclerosis	0.000131	0.000509	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—multiple sclerosis	0.000131	0.000508	CcSEcCtD
Nefazodone—Vomiting—Dexamethasone—multiple sclerosis	0.00013	0.000505	CcSEcCtD
Nefazodone—Vomiting—Betamethasone—multiple sclerosis	0.00013	0.000505	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—multiple sclerosis	0.000129	0.000502	CcSEcCtD
Nefazodone—Rash—Dexamethasone—multiple sclerosis	0.000129	0.0005	CcSEcCtD
Nefazodone—Rash—Betamethasone—multiple sclerosis	0.000129	0.0005	CcSEcCtD
Nefazodone—Dermatitis—Dexamethasone—multiple sclerosis	0.000128	0.0005	CcSEcCtD
Nefazodone—Dermatitis—Betamethasone—multiple sclerosis	0.000128	0.0005	CcSEcCtD
Nefazodone—Headache—Betamethasone—multiple sclerosis	0.000128	0.000497	CcSEcCtD
Nefazodone—Headache—Dexamethasone—multiple sclerosis	0.000128	0.000497	CcSEcCtD
Nefazodone—Asthenia—Prednisone—multiple sclerosis	0.000127	0.000496	CcSEcCtD
Nefazodone—Pain—Methotrexate—multiple sclerosis	0.000127	0.000494	CcSEcCtD
Nefazodone—Pruritus—Prednisone—multiple sclerosis	0.000126	0.000489	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—multiple sclerosis	0.000122	0.000476	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—multiple sclerosis	0.000121	0.000473	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000121	0.000472	CcSEcCtD
Nefazodone—Nausea—Betamethasone—multiple sclerosis	0.000121	0.000471	CcSEcCtD
Nefazodone—Nausea—Dexamethasone—multiple sclerosis	0.000121	0.000471	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—multiple sclerosis	0.000118	0.000459	CcSEcCtD
Nefazodone—Dizziness—Prednisone—multiple sclerosis	0.000117	0.000457	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—multiple sclerosis	0.000117	0.000457	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—multiple sclerosis	0.000117	0.000457	CcSEcCtD
Nefazodone—Vomiting—Prednisone—multiple sclerosis	0.000113	0.000439	CcSEcCtD
Nefazodone—Rash—Prednisone—multiple sclerosis	0.000112	0.000436	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—multiple sclerosis	0.000112	0.000435	CcSEcCtD
Nefazodone—Headache—Prednisone—multiple sclerosis	0.000111	0.000433	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—multiple sclerosis	0.000109	0.000425	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—multiple sclerosis	0.000106	0.000414	CcSEcCtD
Nefazodone—Nausea—Prednisone—multiple sclerosis	0.000105	0.00041	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—multiple sclerosis	0.000105	0.000409	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—multiple sclerosis	0.000102	0.000395	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—multiple sclerosis	9.81e-05	0.000382	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—multiple sclerosis	9.43e-05	0.000367	CcSEcCtD
Nefazodone—Rash—Methotrexate—multiple sclerosis	9.35e-05	0.000364	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—multiple sclerosis	9.35e-05	0.000364	CcSEcCtD
Nefazodone—Headache—Methotrexate—multiple sclerosis	9.29e-05	0.000362	CcSEcCtD
Nefazodone—Nausea—Methotrexate—multiple sclerosis	8.81e-05	0.000343	CcSEcCtD
Nefazodone—HTR1A—Signaling Pathways—PTGER4—multiple sclerosis	2.34e-05	0.000288	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTGER4—multiple sclerosis	2.33e-05	0.000287	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL3—multiple sclerosis	2.32e-05	0.000285	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PGR—multiple sclerosis	2.31e-05	0.000284	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	2.31e-05	0.000284	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	2.3e-05	0.000283	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PGR—multiple sclerosis	2.29e-05	0.000282	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.29e-05	0.000281	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CCR5—multiple sclerosis	2.29e-05	0.000281	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	2.28e-05	0.000281	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCR3—multiple sclerosis	2.26e-05	0.000278	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	2.25e-05	0.000277	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL2RA—multiple sclerosis	2.25e-05	0.000277	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	2.25e-05	0.000277	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCR3—multiple sclerosis	2.25e-05	0.000277	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CD28—multiple sclerosis	2.24e-05	0.000276	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.24e-05	0.000276	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	2.24e-05	0.000275	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.23e-05	0.000275	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTGER4—multiple sclerosis	2.23e-05	0.000275	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CD28—multiple sclerosis	2.23e-05	0.000274	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	2.2e-05	0.000271	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCR2—multiple sclerosis	2.2e-05	0.000271	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PGR—multiple sclerosis	2.2e-05	0.00027	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.19e-05	0.00027	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCR2—multiple sclerosis	2.19e-05	0.000269	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCR3—multiple sclerosis	2.15e-05	0.000265	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CD28—multiple sclerosis	2.13e-05	0.000263	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	2.1e-05	0.000259	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCR2—multiple sclerosis	2.1e-05	0.000258	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	2.09e-05	0.000258	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.09e-05	0.000257	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	2.08e-05	0.000256	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	2.07e-05	0.000255	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—POMC—multiple sclerosis	2.07e-05	0.000254	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	2.06e-05	0.000253	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—POMC—multiple sclerosis	2.06e-05	0.000253	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	2.05e-05	0.000252	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	2.04e-05	0.000252	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CNR1—multiple sclerosis	2.03e-05	0.00025	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	2.03e-05	0.00025	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	2.02e-05	0.000249	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CNR1—multiple sclerosis	2.02e-05	0.000249	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—BCHE—multiple sclerosis	2.02e-05	0.000248	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	2e-05	0.000246	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PGR—multiple sclerosis	1.99e-05	0.000245	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	1.98e-05	0.000244	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.97e-05	0.000243	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.97e-05	0.000243	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—POMC—multiple sclerosis	1.97e-05	0.000242	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	1.95e-05	0.000241	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	1.95e-05	0.00024	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CD28—multiple sclerosis	1.94e-05	0.000238	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CNR1—multiple sclerosis	1.93e-05	0.000238	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	1.91e-05	0.000235	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	1.91e-05	0.000235	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	1.9e-05	0.000234	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IL2—multiple sclerosis	1.9e-05	0.000234	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	1.9e-05	0.000233	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	1.89e-05	0.000232	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—POMC—multiple sclerosis	1.88e-05	0.000231	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—POMC—multiple sclerosis	1.87e-05	0.00023	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	1.86e-05	0.000229	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	1.86e-05	0.000229	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.85e-05	0.000227	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	1.84e-05	0.000227	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—CCL2—multiple sclerosis	1.84e-05	0.000226	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL10—multiple sclerosis	1.83e-05	0.000225	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—CCL2—multiple sclerosis	1.83e-05	0.000225	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL10—multiple sclerosis	1.82e-05	0.000224	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	1.81e-05	0.000223	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.8e-05	0.000222	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—POMC—multiple sclerosis	1.79e-05	0.00022	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	1.78e-05	0.00022	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	1.78e-05	0.000219	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	1.76e-05	0.000217	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	1.75e-05	0.000216	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—CCL2—multiple sclerosis	1.75e-05	0.000215	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	1.75e-05	0.000215	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL10—multiple sclerosis	1.74e-05	0.000214	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	1.73e-05	0.000213	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	1.72e-05	0.000211	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—TYK2—multiple sclerosis	1.67e-05	0.000205	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—TYK2—multiple sclerosis	1.66e-05	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	1.62e-05	0.0002	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	1.62e-05	0.000199	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CD86—multiple sclerosis	1.6e-05	0.000197	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	1.6e-05	0.000196	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CD86—multiple sclerosis	1.59e-05	0.000196	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—TYK2—multiple sclerosis	1.59e-05	0.000195	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	1.59e-05	0.000195	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	1.59e-05	0.000195	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	1.58e-05	0.000194	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	1.57e-05	0.000194	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	1.57e-05	0.000193	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	1.55e-05	0.000191	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	1.55e-05	0.00019	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—APOE—multiple sclerosis	1.54e-05	0.000189	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	1.53e-05	0.000188	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CD86—multiple sclerosis	1.52e-05	0.000187	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	1.52e-05	0.000187	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL5—multiple sclerosis	1.5e-05	0.000184	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.5e-05	0.000184	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	1.48e-05	0.000182	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	1.47e-05	0.000181	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	1.46e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—IL2—multiple sclerosis	1.45e-05	0.000179	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	1.45e-05	0.000179	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	1.45e-05	0.000178	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	1.44e-05	0.000178	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	1.44e-05	0.000177	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	1.44e-05	0.000177	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	1.42e-05	0.000175	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	1.41e-05	0.000174	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	1.41e-05	0.000174	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.4e-05	0.000173	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	1.4e-05	0.000172	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—BCHE—multiple sclerosis	1.39e-05	0.000172	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	1.39e-05	0.000171	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SPP1—multiple sclerosis	1.39e-05	0.000171	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	1.39e-05	0.000171	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.38e-05	0.00017	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	1.38e-05	0.00017	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.36e-05	0.000167	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	1.35e-05	0.000166	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCR5—multiple sclerosis	1.35e-05	0.000166	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	1.33e-05	0.000164	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2RA—multiple sclerosis	1.33e-05	0.000164	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL2—multiple sclerosis	1.32e-05	0.000163	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—POMC—multiple sclerosis	1.32e-05	0.000163	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.32e-05	0.000162	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.31e-05	0.000162	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	1.31e-05	0.000161	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	1.29e-05	0.000159	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APOE—multiple sclerosis	1.29e-05	0.000159	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APOE—multiple sclerosis	1.28e-05	0.000158	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.26e-05	0.000155	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	1.26e-05	0.000155	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	1.24e-05	0.000152	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	1.23e-05	0.000152	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOE—multiple sclerosis	1.23e-05	0.000151	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.22e-05	0.000151	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—multiple sclerosis	1.21e-05	0.000149	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.21e-05	0.000149	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ALB—multiple sclerosis	1.2e-05	0.000148	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	1.2e-05	0.000148	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	1.2e-05	0.000148	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.2e-05	0.000147	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	1.18e-05	0.000145	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	1.17e-05	0.000144	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CD80—multiple sclerosis	1.17e-05	0.000144	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CD80—multiple sclerosis	1.16e-05	0.000143	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	1.15e-05	0.000141	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	1.11e-05	0.000137	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.11e-05	0.000137	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—multiple sclerosis	1.11e-05	0.000137	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CD80—multiple sclerosis	1.11e-05	0.000137	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—POMC—multiple sclerosis	1.11e-05	0.000136	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—POMC—multiple sclerosis	1.1e-05	0.000136	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	1.1e-05	0.000135	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	1.09e-05	0.000134	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	1.09e-05	0.000134	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.08e-05	0.000133	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.08e-05	0.000133	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.06e-05	0.000131	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.06e-05	0.00013	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	1.06e-05	0.00013	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—POMC—multiple sclerosis	1.04e-05	0.000128	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	1.03e-05	0.000127	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	1.01e-05	0.000125	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.01e-05	0.000124	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.01e-05	0.000124	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	9.87e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	9.85e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	9.8e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—POMC—multiple sclerosis	9.57e-06	0.000118	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—POMC—multiple sclerosis	9.55e-06	0.000117	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ALB—multiple sclerosis	9.5e-06	0.000117	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	9.38e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	9.37e-06	0.000115	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	9.37e-06	0.000115	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	9.17e-06	0.000113	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	9.17e-06	0.000113	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	9.16e-06	0.000113	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	8.97e-06	0.00011	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	8.71e-06	0.000107	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ALB—multiple sclerosis	8.7e-06	0.000107	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—BCHE—multiple sclerosis	8.59e-06	0.000106	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	8.52e-06	0.000105	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	8.51e-06	0.000105	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—multiple sclerosis	8.38e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	8.34e-06	0.000103	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	8.33e-06	0.000103	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—multiple sclerosis	8.19e-06	0.000101	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	8.15e-06	0.0001	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—multiple sclerosis	8.15e-06	0.0001	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	8.11e-06	9.98e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—multiple sclerosis	7.9e-06	9.72e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	7.8e-06	9.6e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	7.76e-06	9.55e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	7.75e-06	9.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	7.74e-06	9.52e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	7.71e-06	9.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	7.38e-06	9.09e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—POMC—multiple sclerosis	7.2e-06	8.87e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—multiple sclerosis	7.08e-06	8.71e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	7.04e-06	8.67e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	6.93e-06	8.53e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	6.9e-06	8.49e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	6.89e-06	8.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	6.86e-06	8.44e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—POMC—multiple sclerosis	6.79e-06	8.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	6.7e-06	8.24e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—multiple sclerosis	6.57e-06	8.08e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	6.57e-06	8.08e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	6.56e-06	8.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	6.44e-06	7.93e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	6.41e-06	7.89e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—multiple sclerosis	6.41e-06	7.88e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	6.39e-06	7.87e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—multiple sclerosis	6.37e-06	7.84e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	6.36e-06	7.82e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	6.27e-06	7.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	6.23e-06	7.67e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—multiple sclerosis	6.19e-06	7.62e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	6.1e-06	7.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	6.09e-06	7.5e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	6.09e-06	7.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	5.97e-06	7.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	5.96e-06	7.33e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	5.83e-06	7.18e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—multiple sclerosis	5.53e-06	6.81e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	5.52e-06	6.79e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	5.42e-06	6.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	5.42e-06	6.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	5.41e-06	6.66e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	5.41e-06	6.65e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	5.3e-06	6.52e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—multiple sclerosis	5.17e-06	6.36e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	5.03e-06	6.2e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	5.02e-06	6.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	4.93e-06	6.06e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—multiple sclerosis	4.82e-06	5.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—multiple sclerosis	4.79e-06	5.9e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	4.59e-06	5.64e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—POMC—multiple sclerosis	4.44e-06	5.46e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—multiple sclerosis	4.16e-06	5.12e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	4.07e-06	5.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—multiple sclerosis	4.05e-06	4.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	3.78e-06	4.66e-05	CbGpPWpGaD
